{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:56:22Z","timestamp":1762642582088,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["269855","269855"],"award-info":[{"award-number":["269855","269855"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Continuous use of amphetamines, alcohol, benzodiazepines, cannabis, cocaine, or opioids contributes to health impairments, increased morbidity, and overdose deaths among patients with substance use disorders (SUDs). This study evaluates the impact of inpatient detoxification, injecting substance use, age, and gender on substance use over time among patients undergoing outpatient SUD treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used data from a cohort of SUD patients in Norway obtained from health assessments of self-reported substance use and sociodemographic and clinical factors. A total of 881 substance use measurements, including substances and frequency of use, were assessed for 708 SUD patients in 2016\u20132020. Of those, 171 patients provided two or more substance use measurements. The total substance use was calculated, creating a substance use severity index (SUSI), ranging from zero (no use) to one (daily use of all substances). We defined <jats:italic>baseline<\/jats:italic> as the first substance use measurement when the measurements were listed chronologically. <jats:italic>Time<\/jats:italic> was defined as years from baseline. We used a linear mixed model to analyze the SUSI at baseline and over time, and its associations with inpatient detoxification, injecting substance use, gender, and age, presented with coefficients and 95% confidence intervals (CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No longitudinal changes in the SUSI were found compared with baseline (change in SUSI (cSUSI): 0.04, 95% CI: \u2212\u20090.05;0.13, <jats:italic>p<\/jats:italic>\u2009=\u20090.397). Likewise, \u201cinpatient detoxification\u201d was not associated with changes in the SUSI compared with \u201cno inpatient detoxification\u201d (cSUSI: 0.00, 95% CI: \u2212\u20090.04;0.04, <jats:italic>p<\/jats:italic>\u2009=\u20090.952). However, injecting substances were associated with a higher SUSI than not injecting substances at baseline (difference in SUSI: 0.19, 95% CI: 0.16;0.21, <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001), and starting to inject substances was associated with increasing SUSI over time compared with not starting to inject substances (cSUSI: 0.11, 95% CI: 0.07;0.15, <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001). Gender was not significantly associated with changes in the SUSI (cSUSI: \u2212\u20090.04, 95% CI: \u2212\u20090.07;0.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.052), while patients over 60\u2009years of age had a lower SUSI than those under the age of 30 at baseline (difference in SUSI: \u2212\u20090.08, 95% CI: \u2212\u20090.14;\u2212\u20090.01, <jats:italic>p<\/jats:italic>\u2009=\u20090.018), with no change over time (cSUSI: \u2212\u20090.05, 95% CI: \u2212\u20090.16;0.05, <jats:italic>p<\/jats:italic>\u2009=\u20090.297).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present study demonstrates that inpatient detoxification was not associated with substance use changes over time for patients undergoing outpatient SUD treatment. Otherwise, injecting substance use was a particular risk factor for a high level of substance use. Future research needs to evaluate the impact of other treatment approaches on substance use, ideally in randomized controlled trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-021-00403-9","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:04:18Z","timestamp":1631700258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-7638","authenticated-orcid":false,"given":"J\u00f8rn Henrik","family":"Vold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Chalabianloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer F.","family":"Aas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"403_CR1","unstructured":"Polydrug use: patterns and responses. In. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/534\/EMCDDA_SI09_polydrug_use_187893.pdf: European Monitoring Centre for Drugs and Drug Addiction. Luxembourg: Publications Office of the European Union; 2009. Accessed 29 Aug\u00a02021."},{"key":"403_CR2","unstructured":"Results from the 2018 National Survey on Drug Use and Health: Detailed tables. In. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https:\/\/www.samhsa.gov\/data\/: Substance Abuse and Mental Health Services Administration; 2019. Accessed\u00a020\u00a0Aug\u00a02019."},{"key":"403_CR3","unstructured":"World Drug Report 2020, booklet 4. In. https:\/\/wdr.unodc.org\/uploads\/wdr2020\/documents\/WDR20_BOOKLET_4.pdf: United Nations Office on Drugs and Crime; 2020. Accessed 26 Mar\u00a02021."},{"key":"403_CR4","volume-title":"Polydrug use: patterns and responses","author":"European Monitoring Centre for D, Drug A","year":"2009","unstructured":"European Monitoring Centre for D, Drug A. Polydrug use: patterns and responses. Luxembourg: Luxembourg : Publications Office of the European Union; 2009."},{"key":"403_CR5","unstructured":"The European Union Drug Strategy 2021-25. In. https:\/\/data.consilium.europa.eu\/doc\/document\/ST-14178-2020-INIT\/en\/pdf: Euroepan Union; 2020. Accessed 4 May\u00a02021."},{"issue":"9","key":"403_CR6","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","volume":"103","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction. 2008;103(9):1484\u201392. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02249.x.","journal-title":"Addiction"},{"key":"403_CR7","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"key":"403_CR8","doi-asserted-by":"publisher","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people.\u00a0Cochrane Database Syst Rev.\u00a02016;5:CD011117. https:\/\/doi.org\/10.1002\/14651858.CD011117.pub2. Accessed 9 Sept\u00a02021.","DOI":"10.1002\/14651858.CD011117.pub2"},{"issue":"3","key":"403_CR9","first-page":"Cd002209","volume":"2009","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):Cd002209.","journal-title":"Cochrane Database Syst Rev"},{"key":"403_CR10","doi-asserted-by":"publisher","unstructured":"Livingston N, Ameral V, Hocking E, Leviyah X, Timko C. Interventions to improve post-detoxification treatment engagement and alcohol recovery: systematic review of intervention types and effectiveness. Alcohol Alcohol. 2021. https:\/\/doi.org\/10.1093\/alcalc\/agab021.","DOI":"10.1093\/alcalc\/agab021"},{"key":"403_CR11","doi-asserted-by":"publisher","unstructured":"Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence.\u00a0Cochrane Database Syst Rev. 2005;2:CD004580. https:\/\/doi.org\/10.1002\/14651858.CD004580.pub2. Accessed 9 Sept 2021.","DOI":"10.1002\/14651858.CD004580.pub2"},{"issue":"6","key":"403_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1037\/0022-006X.70.6.1224","volume":"70","author":"TD Armstrong","year":"2002","unstructured":"Armstrong TD, Costello EJ. Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity. J Consult Clin Psychol. 2002;70(6):1224\u201339. https:\/\/doi.org\/10.1037\/0022-006X.70.6.1224.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"403_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/17522439.2011.639901","volume":"4","author":"KT Mueser","year":"2012","unstructured":"Mueser KT, Gottlieb JD, Cather C, Glynn SM, Zarate R, Smith LF, et al. Antisocial personality disorder in people with co-occurring severe mental illness and substance use disorders: clinical, functional, and family relationship correlates. Psychosis. 2012;4(1):52\u201362. https:\/\/doi.org\/10.1080\/17522439.2011.639901.","journal-title":"Psychosis"},{"issue":"5","key":"403_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/WNF.0b013e318261e193","volume":"35","author":"S Ross","year":"2012","unstructured":"Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35(5):235\u201343. https:\/\/doi.org\/10.1097\/WNF.0b013e318261e193.","journal-title":"Clin Neuropharmacol"},{"key":"403_CR15","unstructured":"World Drug Report 2020, booklet 2. In. https:\/\/wdr.unodc.org\/uploads\/wdr2020\/documents\/WDR20_Booklet_2.pdf: United Nations Office on Drugs and Crime; 2020. Accessed 6 Apr\u00a02021."},{"key":"403_CR16","unstructured":"Global hepatitis report 2017. In. https:\/\/www.who.int\/publications\/i\/item\/global-hepatitis-report-2017: World Health Organization; 2017. Accessed 29 Aug\u00a02021."},{"issue":"1","key":"403_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13011-020-00286-2","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, et al. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy. 2020;15(1):44. https:\/\/doi.org\/10.1186\/s13011-020-00286-2.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"403_CR18","unstructured":"Drug-related deaths and mortality in Europe - update from the EMCDDA expert network. In. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/11485\/20193286_TD0319444ENN_PDF.pdf: European Monitoring Centre for Drugs and Drug Addiction; 2019. Accessed 4 Apr\u00a02021."},{"issue":"8","key":"403_CR19","doi-asserted-by":"publisher","first-page":"e036355","DOI":"10.1136\/bmjopen-2019-036355","volume":"10","author":"CF Aas","year":"2020","unstructured":"Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, \u00d8kland JM, et al. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open. 2020;10(8):e036355. https:\/\/doi.org\/10.1136\/bmjopen-2019-036355.","journal-title":"BMJ Open"},{"issue":"4","key":"403_CR20","doi-asserted-by":"publisher","first-page":"e202361","DOI":"10.1001\/jamanetworkopen.2020.2361","volume":"3","author":"ME Tori","year":"2020","unstructured":"Tori ME, Larochelle MR, Naimi TS. Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017. JAMA Netw Open. 2020;3(4):e202361. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2361.","journal-title":"JAMA Netw Open"},{"key":"403_CR21","unstructured":"Perspectives on drugs: the misuse of benzodiazepines among high-risk opioid users in Europe. In. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2733\/Misuse%20of%20benzos_POD2015.pdf (dated: January 28, 2021): European Monitoring Centre for Drugs and Drug Addiction; 2018."},{"key":"403_CR22","unstructured":"Nava F. In: Presentation at the messing \u2018Continuity and change: high-risk drug use and drug treatment in Europe 2014\u2019: 2014; 23\u201326 September, Lisbon: http:\/\/www.emcdda.europa.eu\/activities\/expert-meetings\/2014\/ki-event; 2014. Accessed 29 Aug\u00a02021."},{"key":"403_CR23","volume-title":"Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings","author":"World Health Organization. Regional Office for the Western P","year":"2009","unstructured":"World Health Organization. Regional Office for the Western P. Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings. Manila: WHO Regional Office for the Western Pacific; 2009."},{"key":"403_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.addbeh.2018.11.008","volume":"90","author":"HW Andersson","year":"2019","unstructured":"Andersson HW, Wenaas M, Nordfj\u00e6rn T. Relapse after inpatient substance use treatment: a prospective cohort study among users of illicit substances. Addict Behav. 2019;90:222\u20138. https:\/\/doi.org\/10.1016\/j.addbeh.2018.11.008.","journal-title":"Addict Behav"},{"issue":"10","key":"403_CR25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1360-0443.1994.tb03309.x","volume":"89","author":"E Oppenheimer","year":"1994","unstructured":"Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994;89(10):1299\u2013308. https:\/\/doi.org\/10.1111\/j.1360-0443.1994.tb03309.x.","journal-title":"Addiction"},{"issue":"7396","key":"403_CR26","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1136\/bmj.326.7396.959","volume":"326","author":"J Strang","year":"2003","unstructured":"Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. Bmj. 2003;326(7396):959\u201360. https:\/\/doi.org\/10.1136\/bmj.326.7396.959.","journal-title":"Bmj"},{"issue":"2\u20133","key":"403_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.drugalcdep.2006.12.019","volume":"89","author":"JD Wines Jr","year":"2007","unstructured":"Wines JD Jr, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. Overdose after detoxification: a prospective study. Drug Alcohol Depend. 2007;89(2\u20133):161\u20139. https:\/\/doi.org\/10.1016\/j.drugalcdep.2006.12.019.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"403_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1186\/s12879-019-4598-7","volume":"19","author":"LT Fadnes","year":"2019","unstructured":"Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):943. https:\/\/doi.org\/10.1186\/s12879-019-4598-7.","journal-title":"BMC Infect Dis"},{"key":"403_CR29","unstructured":"Lobmaier P, Skeie I, Lillevold P, Waal H, Bussesund K, Clausen T. LAR statusrapport 2019 - nye medisiner - nye muligheter? In. https:\/\/www.med.uio.no\/klinmed\/forskning\/sentre\/seraf\/publikasjoner\/rapporter\/2020\/seraf-rapport-nr-1-2020-statusrapport-2019.pdf: The Norwegian Centre for Addiction Research (Norwegian: Senter for rus- og avhengighetsforskning (SERAF)); 2020. Accessed 28 Jan\u00a02021."},{"issue":"1\u20132","key":"403_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0376-8716(96)01290-2","volume":"43","author":"SH Dinwiddie","year":"1996","unstructured":"Dinwiddie SH, Cottler L, Compton W, Abdallah AB. Psychopathology and HIV risk behaviors among injection drug users in and out of treatment. Drug Alcohol Depend. 1996;43(1\u20132):1\u201311. https:\/\/doi.org\/10.1016\/S0376-8716(96)01290-2.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"403_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0706743716632503","volume":"61","author":"\u00c9 Roy","year":"2016","unstructured":"Roy \u00c9, Arruda N, Bruneau J, Jutras-Aswad D. Epidemiology of injection drug use: new trends and prominent issues. Can J Psychiatr. 2016;61(3):136\u201344. https:\/\/doi.org\/10.1177\/0706743716632503.","journal-title":"Can J Psychiatr"},{"key":"403_CR32","unstructured":"Trends in injecting drug use in Europe. In. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/614\/EMCDDA_SI10_injecting_217651.pdf: European Monitoring Centre for Drugs and Drug Addiction; 2010. Accessed 8 Apr\u00a02021."},{"issue":"6","key":"403_CR33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.socscimed.2004.06.052","volume":"60","author":"M Donald","year":"2005","unstructured":"Donald M, Dower J, Kavanagh D. Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. Soc Sci Med. 2005;60(6):1371\u201383. https:\/\/doi.org\/10.1016\/j.socscimed.2004.06.052.","journal-title":"Soc Sci Med"},{"key":"403_CR34","first-page":"1","volume-title":"The CBHSQ report. edn","author":"RN Lipari","year":"2013","unstructured":"Lipari RN, Van Horn SL. Trends in substance use disorders among adults aged 18 or older. In: The CBHSQ report. edn. Rockville: Substance Abuse and Mental Health Services Administration (US); 2013. p. 1\u201310."},{"issue":"576","key":"403_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3399\/bjgp10X514710","volume":"60","author":"C Beynon","year":"2010","unstructured":"Beynon C, Stimson G, Lawson E. Illegal drug use in the age of ageing. Br J Gen Pract. 2010;60(576):481\u20132. https:\/\/doi.org\/10.3399\/bjgp10X514710.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"403_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0269881116675508","volume":"31","author":"A Bakker","year":"2017","unstructured":"Bakker A, Streel E. Benzodiazepine maintenance in opiate substitution treatment: good or bad? A retrospective primary care case-note review. J Psychopharmacol. 2017;31(1):62\u20136. https:\/\/doi.org\/10.1177\/0269881116675508.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"403_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12913-020-05195-5","volume":"20","author":"JH Vold","year":"2020","unstructured":"Vold JH, Skurtveit S, Aas C, Chalabianloo F, Kloster PS, Johansson KA, et al. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. BMC Health Serv Res. 2020;20(1):352. https:\/\/doi.org\/10.1186\/s12913-020-05195-5.","journal-title":"BMC Health Serv Res"},{"key":"403_CR38","unstructured":"Global Burden of Disease Study 2017 (GBD 2017). In. http:\/\/ghdx.healthdata.org\/gbd-results-tool: Seattle, United States: Institute for Health Metrics and Evaluation (IHME), Global Burden of Disease Collaborative Network; 2018. Accessed 10 Apr\u00a02021."}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00403-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-021-00403-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00403-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:15:48Z","timestamp":1631700948000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-021-00403-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1186\/s13011-021-00403-9","relation":{},"ISSN":["1747-597X"],"issn-type":[{"type":"electronic","value":"1747-597X"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"29 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been reviewed and approved by the Regional Ethical Committee for Health Research (REC) West, Norway (reference number: 2017\/51\/REK Vest, dated 29.03.2017\/20.04.2017). Each patient provided written informed consent prior to enrolling in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants have consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}